JAK2V617F mutation in myelodysplastic syndrome (MDS) with del(5q) arises in genetically discordant clones

Leukemia Research

Volumn 34, Issue 6, 2010, Pages 821-823

  Sokol, L ^a   Caceres, G ^a   Rocha, K ^a   Stockero, K J ^b   Dewald, D W ^b   List, A F ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b MAYO CLINIC   (United States)

Author keywords

5q syndrome; Clonality; JAK2V617; Mutation; Myelodysplastic syndromes

Indexed keywords

IDURONATE 2 SULFATASE; JANUS KINASE 2;

5Q- SYNDROME; ADULT; ARTICLE; BURST FORMING UNIT E; CASE REPORT; CELL GROWTH; CHROMOSOME 5Q; CLINICAL FEATURE; COLONY FORMING UNIT; CONTROLLED STUDY; DIPLOIDY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE MUTATION; GENETIC POLYMORPHISM; GRANULOCYTE; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; MOLECULAR CLONING; MONOCYTE; PRIORITY JOURNAL; THROMBOCYTOSIS;

AMINO ACID SUBSTITUTION; CHROMOSOME DELETION; CHROMOSOMES, HUMAN, PAIR 5; CLONE CELLS; ERYTHROID PRECURSOR CELLS; FEMALE; HUMANS; JANUS KINASE 2; MIDDLE AGED; MUTATION, MISSENSE; MYELODYSPLASTIC SYNDROMES; PHENYLALANINE; VALINE;

EID: 77952097487     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2009.09.016     Document Type: Article

References (14)

1. Malcovati L., Nimer S.D. Myelodysplastic syndromes: diagnosis and staging. Cancer Control 2008, 15:4-13.
2. Steensma D.P., List A.F. Genetic testing in the myelodysplastic syndromes: molecular insights into hematologic diversity. Mayo Clin Proc 2005, 80:681-698.
3. Giagounidis A.A.N., Germing U., Aul C. Biological and prognostic significance of chromosome 5q deletions in myeloid malignancies. Clin Cancer Res 2006, 12:5-10.
4. Kralovics R. Genetic complexity of myeloproliferative neoplasm. Leukemia 2008, 22:1841-1848.
5. Steensma D.P., Dewald D.W., Lasho T.L., Powell H.L., McClure R.F., Levine R.L., et al. The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both " atypical" myeloproliferative disorders and myelodysplastic syndromes. Blood 2005, 106:1207-1209.
6. Szpurka H., Tiu R., Murugesan G., Aboudola S., His E.D., Theil K.S., et al. Refractory anemia with ringed sideroblasts associated with marked thrombocytosis (RARS-T), another myeloproliferative condition characterized by JAK2 V617F mutation. Blood 2006, 108:2173-2181.
7. Ingram W., Lea N.C., Cervera J., Germing U., Fenaux P., Cassinat B., et al. The JAK2 V617F mutation identifies a subgroup of MDS patients with isolated deletion 5q and a proliferative bone marrow. Leukemia 2006, 20:1319-1321.
8. WHO classification of tumours of haematopoietic and lymphoid tissues 2008, IARC, Lyon. S.H. Swerdlow, E. Campo, N.L. Harris, E.S. Jaffe, S.A. Pileri, H. Stein (Eds.).
9. Gregg X.T., Kralovics R., Prchal J.T. A polymorphism of the X-linked gene IDS increases the number of females informative for transcriptional clonality assays. Am J Hematol 2000, 63:184-191.
10. Baxter E.J., Scott L.M., Campbell P.J., East C., Fourouclas N., Swanton S., et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005, 365:1054-1061.
11. Cherry A.M., Brockman S.R., Paternoster S.F., Hicks G.A., Neuberg D., Higgins R.R., et al. Comparison of interphase FISH and metaphase cytogenetics to study myelodysplastic syndrome: an Eastern Cooperative Oncology Group (ECOG) study. Leukemia Res 2003, 27:1085-1090.
12. Li S., Kralovics R., De Libero G., Theocharides A., Gisslinger H., Skoda R.C. Clonal heterogeneity in polycythemia vera patients with JAK2 exon12 and JAK2-V617F mutations. Blood 2008, 111:3863-3866.
13. Beer P.A., Jones A.V., Bench A.J., Goday-Fernandez A., Boyd E.M., Vaghela K.J., et al. Clonal diversity in the myeloproliferative neoplasms: independent origins of genetically distinct clones. Br J Haematol 2009, 144:904-908.
14. Schaub F.X., Jager R., Looser R., Hao-Shen H., Hermouet S., Girodon F., et al. Clonal analysis of deletions on chromosome 20q and JAK2-V617F in MPD suggests that del20q acts independently and is not one of the predisposing mutations for JAK2-617F. Blood 2009, 113:2022-2027.